Head to Head Analysis: Eli Lilly and (LLY) and Adamis Pharmaceuticals (ADMP)
Adamis Pharmaceuticals (NASDAQ: ADMP) and Eli Lilly and (NYSE:LLY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
Earnings & Valuation
This table compares Adamis Pharmaceuticals and Eli Lilly and’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals||$6.47 million||21.42||-$19.43 million||($0.70)||-5.93|
|Eli Lilly and||$21.22 billion||4.43||$2.74 billion||$2.10||40.61|
This table compares Adamis Pharmaceuticals and Eli Lilly and’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eli Lilly and||9.90%||30.27%||10.82%|
Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Adamis Pharmaceuticals does not pay a dividend. Eli Lilly and pays out 99.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and has raised its dividend for 3 consecutive years.
Insider & Institutional Ownership
16.6% of Adamis Pharmaceuticals shares are held by institutional investors. Comparatively, 76.4% of Eli Lilly and shares are held by institutional investors. 12.2% of Adamis Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Adamis Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Adamis Pharmaceuticals and Eli Lilly and, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eli Lilly and||1||5||9||0||2.53|
Adamis Pharmaceuticals currently has a consensus target price of $10.33, suggesting a potential upside of 149.00%. Eli Lilly and has a consensus target price of $94.60, suggesting a potential upside of 10.92%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Adamis Pharmaceuticals is more favorable than Eli Lilly and.
Eli Lilly and beats Adamis Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.